• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection
【24h】

A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection

机译：Sofosbuvir / Velpatasvir治疗慢性丙型肝炎感染的Pangenotypic，单级片剂方案

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Hepatitis C virus (HCV) infects nearly 170 million people worldwide and is a leading cause of progressive liver damage, cirrhosis, and hepatocellular carcinoma. Curative therapies have historically relied on interferon-based treatments and were limited by significant toxicity and poor response rates, particularly among patients with prior treatment failure and advanced hepatic fibrosis. The recent advent of direct acting antiviral (DAA) agents which target key steps in the HCV viral life cycle has transformed the landscape of HCV treatment by offering highly effective and well tolerated interferon-free treatments. However, current therapies are genotype-specific and have variable efficacy amongst less prevalent HCV variants. Areas covered: This review covers the preclinical and clinical development of sofosbuvir/velpatasvir (SOF/VEL), an interferon-free, once daily, pangenotypic treatment for the treatment of chronic hepatitis C virus (HCV) infection. All relevant literature from 2014 through September of 2016 is included. Expert opinion: SOF/VEL offers the promise of a single tablet, interferon- and ribavirin-free treatment that has extremely high efficacy in persons with chronic HCV infection regardless of genotype, subtype, treatment history or fibrosis status. It is expected to play a major role on a global scale in the therapeutic armamentarium against this ubiquitous threat to human health.
机译：介绍：丙型肝炎病毒（HCV）在全球近170万人感染，是渐进性肝损伤，肝硬化和肝细胞癌的主要原因。治疗疗法历史依赖于基于干扰素的治疗，并且受到显着的毒性和较差的反应率的限制，特别是患有先前治疗失败和晚期肝纤维化的患者。最近出现直接作用抗病毒（DAA）试剂，其靶向HCV病毒生命周期的关键步骤，通过提供高效和耐受性的无干扰素治疗来改变HCV处理的景观。然而，目前的疗法是基因型特异性并且在不太普遍的HCV变体中具有可变功效。所涵盖的地区：本综述涵盖了Sofosbuvir / Velpatasvir（SOF / VEL）的临床前和临床开发，无干扰素，每日一次，Pangenotypic治疗治疗慢性丙型肝炎病毒（HCV）感染。包括2014年至2016年9月的所有相关文献。专家意见：SOF / VEL提供单片机，干扰素和利巴韦林的治疗方法，无论基因型，亚型，治疗史或纤维化状态如何，对慢性HCV感染的人具有极高的疗效。预计将在治疗武器中的全球范围内发挥重要作用，免受对人类健康的这种无处不在的威胁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号